HIV Drug Lenacapavir Disrupts Virus Assembly, Creating Giant Noninfectious Particles
Researchers at Kumamoto University have identified a secondary mechanism by which the HIV drug lenacapavir inhibits the virus, revealing that the treatment disrupts the assembly of new particles to create abnormally large, noninfectious structures.
- Lenacapavir binds to both mature and precursor Gag proteins, causing the assembly of dysfunctional, giant virus-like particles.
- These oversized particles, exceeding 200 nanometers in diameter, are unable to establish a productive infection in target cells.
- The findings, published in the Proceedings of the National Academy of Sciences, clarify how the drug interferes with the late stages of the viral life cycle.
Disruption of Gag Protein Assembly
Lenacapavir is recognized for its ability to block HIV-1 replication by targeting the virus’s capsid core. While previous research confirmed its role in suppressing reverse transcription and nuclear import, the recent study led by Kazuaki Monde of Kumamoto University and Yasumasa Iwatani of the Hamamatsu University School of Medicine demonstrates that the drug also acts during the late stages of viral assembly.
The research team observed that lenacapavir interacts with the precursor protein Gag, which is essential for building new virus particles. This interaction forces the formation of heterogeneous viral-like particles that measure more than 200 nanometers in diameter. In contrast, typical HIV particles generally measure between 100 and 130 nanometers, Medical Xpress reported.
Comparison of Viral Particle Characteristics
Mechanism of Viral Inhibition
“An important and unexpected finding of our study is that lenacapavir can bind to both precursor Gag and mature Gag, despite differences in their structures and assembly states,” Monde said, as noted by EurekAlert!. Although these oversized particles retain the ability to fuse with target cells, they fail to complete the replication process, rendering them biologically inert.
The study used mass photometry and transmission electron microscopy to analyze these structural changes. The authors said that while p24 ELISA testing previously suggested strong inhibition, the use of more precise assays like RT-dPCR and Vpr-HiBiT revealed that the drug’s effect on viral release is dependent on protease activity.
The research team included representatives from the National Hospital Organization Nagoya Medical Center and the Tokyo University of Technology, with work conducted at the Department of Microbiology at Kumamoto University.
Implications for Future Antiretroviral Development
Understanding these late-stage interactions provides a roadmap for developing next-generation capsid-targeting therapeutics. By identifying how lenacapavir induces these abnormal clusters at the plasma membrane, scientists may be able to refine future drug designs to target multiple stages of the HIV life cycle simultaneously.
Kumamoto University traces its roots to Saishunkan, a Han school of the Kumamoto Domain founded in 1756, and emerged in its modern form on May 31, 1949, through the merger of five institutions including Kumamoto Medical College (1896) and the Fifth High School (1887), a center of western learning in the Meiji era. The university now operates with seven faculties, eight graduate schools, and approximately 10,000 students.
The HIV research was conducted at its Honjo-kuhonji Campus, which houses the Faculty of Medicine and the Center for AIDS Research, one of the university’s specialized institutes focused on infectious disease study.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.
Keep reading
- Key Clinical Takeaways
- Mental Health Diagnoses Rise With Medical Complexity in Children, Study Finds
- WHO Determines DRC Bundibugyo Virus Outbreak Remains Public Health Emergency of International Concern (archyde.com)
- Kumamoto University Study Finds Lenacapavir Creates Giant Noninfectious HIV Particles (time.news)